PEGylated Flavonoid Aspasomes as a Brain-Targeted Nano-Vesicular Platform for Enhanced Neuroprotection in Stress-Induced Cognitive Dysfunction.

Amal Fathy Aladoly, Maha M Amin, Heba Nasr Shalaby, Ahmed F Mohamed, Mohamed Y Zakaria

Abstract read

In one paragraph

Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amal Fathy AladolyLaboratory Evaluation Administration, Egyptian Drug Authority (EDA), Cairo, Egypt.ORCID http://orcid.org/0009-0001-6955-6491

Maha M AminDepartment of Pharmaceutics and Pharmaceutical Industry, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0009-0007-1719-1797

Heba Nasr ShalabyDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-3879-7022

Ahmed F MohamedDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-7678-0643

Mohamed Y ZakariaDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, King Salman International University (KSIU), Ras Sudr, 46612, South Sinai, Egypt. mohamed.yehia@ksiu.edu.eg.ORCID http://orcid.org/0000-0002-0049-8609

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Luteolin (LUT) is a biologically active flavonoid exhibiting significant therapeutic potential against neurodegenerative disorders such as cognitive impairment. Nonetheless, its clinical application is limited by poor aqueous solubility, extensive first-pass metabolism and diminished permeability across the blood-brain barrier (BBB) and consequently, low oral bioavailability. This study aimed to develop PEGylated LUT nano-vesicular delivery systems to enhance brain delivery and therapeutic efficacy. PEGylated LUT-Aspasomes were prepared via thin-film hydration, using Brij 52 for PEGylation. Sixteen formulations were designed using a 2

Indexed as

BrainCognitive DysfunctionFlavonoidsLuteolinNanoparticlesNeuroprotective AgentsPolyethylene GlycolsAnimalsBiological AvailabilityBlood-Brain BarrierCognitive EnhancementDrug CarriersDrug Delivery SystemsDrug LiberationMaleNeuroprotectionDrug CarriersFlavonoidsLuteolinNeuroprotective AgentsPolyethylene Glycolsluteolinnasal to brain deliveryPEGylated Aspasomesstress induced cognitive impairment

Identifiers

PMID42091762

DOI10.1016/j.jpha.2024.101097

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.